SBIR/STTR Research Award
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH ANOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TEICHOS LABORATORIES, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- UGFLPLUM9UP5
- Solicitation number
- PHS2021-1
- Topic code
- 91
Research abstract
The goal of this project is to optimize a novel adjuvant formulation composed of alum and a TLR2 agonist to improve performance of a DTaP subunit vaccine.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- TEICHOS LABORATORIES, LLC. ""AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT"".
- Immunotherapy for Factor VIII Inhibition in Hemophilia A
- A Totally Synthetic Immunostimulator that Targets Toll-like Receptor 2 and NOD2: Toward Improved Influenza Vaccines
Research funding history
4 SBIR/STTR records share this UEI (2021–2023). Reported award amounts total $1,102,613. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services